Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 22, 2025 08:30 ET | Source: OKYO Pharma LTD

OKYO Pharma Announces Registration Pathway with 100 Patient Multi-Center Clinical Trial of Urcosimod in Neuropathic Corneal Pain

LONDON and NEW YORK, Sept. 22, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic...
May 19, 2025 07:00 ET | Source: OKYO Pharma LTD

OKYO Pharma to Present at the GPCRs-Targeted Drug Discovery Summit

LONDON and NEW YORK, May 19, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic...
May 01, 2025 07:00 ET | Source: OKYO Pharma LTD

FDA Grants OKYO Pharma Fast Track Designation to Urcosimod for Neuropathic Corneal Pain

LONDON and NEW YORK, May 01, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod (formerly called OK-101)...
March 31, 2025 08:00 ET | Source: OKYO Pharma LTD

OKYO Pharma Announces Positive Data in Long-Term Stability of Urcosimod

Urcosimod in Phase 2 clinical trial for Neuropathic Corneal Pain shown to have Long-Term StabilityUrcosimod stable in single-use ampoules for more than 2½ yearsFDA requires drug to show long-term...
March 10, 2025 08:30 ET | Source: OKYO Pharma LTD

OKYO Pharma Files for Fast Track Designation with FDA for Urcosimod to Treat Neuropathic Corneal Pain

LONDON and NEW YORK, March 10, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of...
February 12, 2025 07:00 ET | Source: OKYO Pharma LTD

OKYO Pharma Announces OK-101 Officially Assigned USAN : Urcosimod

LONDON and NEW YORK, Feb. 12, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic...